DTP3 is primarily utilized in the field of cancer research and therapy. It functions as a selective inhibitor of the GADD45β/MKK7 complex, which plays a crucial role in the survival and proliferation of certain cancer cells. By targeting this complex, DTP3 induces apoptosis in cancer cells, particularly in multiple myeloma and other malignancies that rely on the NF-κB signaling pathway. Its application is significant in developing targeted therapies that minimize damage to healthy cells, offering a promising approach for treating resistant or aggressive cancers. Additionally, DTP3 is studied for its potential to enhance the efficacy of existing cancer treatments when used in combination therapies.